Screener
Tyra Biosciences, Inc. TYRA IRNMIBC — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220645
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development expenses: | ||
| External research and development expenses by program: | ||
| Dabogratinib LG-UTUC | $2,440 | — |
| Dabogratinib IR NMIBC | 5,248 | 1,290 |
| Dabogratinib ACH | 4,309 | 3,587 |
| Dabogratinib mUC | 1,614 | 3,255 |
| TYRA-430 HCC | 2,046 | 2,293 |
| TYRA-200 ICC | 1,010 | 1,465 |
Item 1. Condensed Financial Statements
FAQ
- What is Tyra Biosciences, Inc.'s IRNMIBC — research and development expense?
- Tyra Biosciences, Inc. (TYRA) reported IRNMIBC — research and development expense of $5.25M in Q1 2026.
- What does IRNMIBC — research and development expense mean?
- This metric represents the total operating costs specifically allocated to the research and development activities for the IRNMIBC clinical program. It captures expenditures related to drug discovery, preclinical studies, and clinical trial execution for this specific therapeutic pipeline asset. Monitoring these costs provides insight into the company's capital allocation strategy and the progress of its precision medicine development efforts.
Ask your AI about Tyra Biosciences, Inc.'s irnmibc — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude